Cooper Companies Inc (NYSE:COO) has been given an average rating of “Hold” by the thirteen analysts that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $268.63.

A number of research analysts have recently weighed in on COO shares. BMO Capital Markets raised their price objective on Cooper Companies from $280.00 to $285.00 and gave the company an “outperform” rating in a research report on Friday, August 31st. Zacks Investment Research upgraded Cooper Companies from a “hold” rating to a “buy” rating and set a $265.00 price objective for the company in a research report on Tuesday, May 22nd. ValuEngine upgraded Cooper Companies from a “sell” rating to a “hold” rating in a research report on Friday, June 15th. Finally, Oppenheimer set a $270.00 price objective on Cooper Companies and gave the company a “hold” rating in a research report on Friday, August 31st.

In related news, Director Allan E. Rubenstein sold 1,500 shares of the stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $265.37, for a total value of $398,055.00. Following the completion of the transaction, the director now owns 3,068 shares of the company’s stock, valued at approximately $814,155.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gary S. Petersmeyer sold 430 shares of the stock in a transaction dated Friday, June 22nd. The shares were sold at an average price of $234.33, for a total transaction of $100,761.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,005 shares of company stock valued at $20,492,936. 1.60% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the stock. Sumitomo Life Insurance Co. lifted its stake in shares of Cooper Companies by 4.2% during the second quarter. Sumitomo Life Insurance Co. now owns 5,143 shares of the medical device company’s stock worth $1,211,000 after buying an additional 206 shares during the period. Bronfman E.L. Rothschild L.P. lifted its stake in shares of Cooper Companies by 6.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,622 shares of the medical device company’s stock worth $853,000 after buying an additional 232 shares during the period. Nomura Asset Management Co. Ltd. lifted its stake in shares of Cooper Companies by 1.3% during the second quarter. Nomura Asset Management Co. Ltd. now owns 19,770 shares of the medical device company’s stock worth $4,655,000 after buying an additional 262 shares during the period. Intrust Bank NA lifted its stake in shares of Cooper Companies by 9.0% during the second quarter. Intrust Bank NA now owns 3,209 shares of the medical device company’s stock worth $756,000 after buying an additional 265 shares during the period. Finally, Washington Capital Management Inc. lifted its stake in shares of Cooper Companies by 16.2% during the second quarter. Washington Capital Management Inc. now owns 2,150 shares of the medical device company’s stock worth $506,000 after buying an additional 300 shares during the period. 97.03% of the stock is owned by hedge funds and other institutional investors.

COO stock traded down $2.40 during trading on Friday, reaching $262.92. The company’s stock had a trading volume of 235,471 shares, compared to its average volume of 323,574. Cooper Companies has a 1 year low of $216.47 and a 1 year high of $267.98. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 2.58. The firm has a market capitalization of $13.03 billion, a PE ratio of 27.11, a PEG ratio of 2.12 and a beta of 0.67.

Cooper Companies (NYSE:COO) last issued its quarterly earnings data on Thursday, August 30th. The medical device company reported $3.00 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.07 by ($0.07). The firm had revenue of $660.00 million for the quarter, compared to analysts’ expectations of $653.44 million. Cooper Companies had a net margin of 5.23% and a return on equity of 17.53%. sell-side analysts forecast that Cooper Companies will post 11.62 EPS for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Article: How Do I Invest in Dividend Stocks

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.